TAS Minutes 11th October 2023(284 KB) - TAS
Date added: 4th Dec 2023
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| BILASTINE | Grey | Allergic rhinoconjunctivitis and urticaria | |
| BIMEKIZUMAB (Bimzelx®) (NEW) | Red | For treating axial spondyloarthritis in adults |
In line with NICE TA918 |
| BIMEKIZUMAB (Bimzelx®)) (NEW) | Red | For treating active psoriatic arthritis in adults. |
In line with NICE TA916 |
| FAECAL MICROBIOME TRANSPLANT (NEW) | Red | Treatment resistant reatment resistant C.difficile | |
| PEGFILGRASTIM (NEW) | Red | Treatment of neutropenia in children and TYA patients | |
| SEMAGLUTIDE (Wegovy®) (UPDATED) | Red | Management of obesity in adolescents |
Only through a specialist weight management service. |
| TIRBANIBULIN (Klisyri®) (NEW) | Green | Grade 1 Actinic Keratoses for the face and scalp |
Single treatment course only – not to be repeated. |
Other Updates on this Website
Recent documents from LLR APC and TAS
TAS Minutes 26th September 2023(223 KB) - TAS
Date added: 4th Dec 2023
LLRAPC Meeting Minutes October 2023(611 KB) - LMSG/LLR APC minutes
Date added: 15th Nov 2023
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more